DongKook Pharmaceutical Co. Ltd Total Liabilities
DongKook Pharmaceutical Co. Ltd total liabilities. Based on the latest financial reports, DongKook Pharmaceutical Co. Ltd (086450) has total liabilities worth ₩320.04 Billion KRW (≈ $216.89 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 086450 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of DongKook Pharmaceutical Co. Ltd (2013–2025)
Total liabilities of DongKook Pharmaceutical Co. Ltd from 2013 to 2025. This chart illustrates how DongKook Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 086450 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
DongKook Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of DongKook Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Samyoung Elec
KO:005680
|
Korea | ₩22.57 Billion |
|
Shinhan Seobu T&D REIT Co Ltd
KO:404990
|
Korea | ₩741.43 Billion |
|
Gesco AG
XETRA:GSC1
|
Germany | €178.97 Million |
|
Ekter SA
AT:EKTER
|
Greece | €43.52 Million |
|
Canaan Inc
NASDAQ:CAN
|
USA | $153.54 Million |
|
Nusantara Pelabuhan Handal Tbk PT
JK:PORT
|
Indonesia | Rp1.25 Trillion |
|
Oyak Yatirim Menkul Degerler AS
IS:OYYAT
|
Turkey | TL12.50 Billion |
|
Power Nickel Inc
V:PNPN
|
Canada | CA$21.16 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down DongKook Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DongKook Pharmaceutical Co. Ltd balance sheet assets.
Liquidity & Leverage Metrics
DongKook Pharmaceutical Co. Ltd Total Liabilities Ratios Explained
DongKook Pharmaceutical Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DongKook Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DongKook Pharmaceutical Co. Ltd (2013–2025)
The table below shows the annual total liabilities of DongKook Pharmaceutical Co. Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩299.16 Billion ≈ $202.73 Million |
+9.11% |
| 2024-12-31 | ₩274.19 Billion ≈ $185.81 Million |
+4.11% |
| 2023-12-31 | ₩263.36 Billion ≈ $178.48 Million |
-1.14% |
| 2022-12-31 | ₩266.39 Billion ≈ $180.53 Million |
-9.85% |
| 2021-12-31 | ₩295.51 Billion ≈ $200.26 Million |
+17.36% |
| 2020-12-31 | ₩251.80 Billion ≈ $170.64 Million |
+38.72% |
| 2019-12-31 | ₩181.51 Billion ≈ $123.01 Million |
+8.54% |
| 2018-12-31 | ₩167.22 Billion ≈ $113.32 Million |
+52.90% |
| 2017-12-31 | ₩109.37 Billion ≈ $74.12 Million |
+24.59% |
| 2016-12-31 | ₩87.78 Billion ≈ $59.49 Million |
+16.76% |
| 2015-12-31 | ₩75.18 Billion ≈ $50.95 Million |
+11.21% |
| 2014-12-31 | ₩67.60 Billion ≈ $45.81 Million |
+20.68% |
| 2013-12-31 | ₩56.02 Billion ≈ $37.96 Million |
-- |
About DongKook Pharmaceutical Co. Ltd
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durak… Read more